Enzymatic DNA Synthesis Market Size, Share, Trends, Industry Analysis Report
By Services (Oligonucleotide Synthesis and Gene Synthesis), By Technology, By Application, By End Use, and By Region – Market Forecast, 2025–2034
- Published Date:Aug-2025
- Pages: 129
- Format: PDF
- Report ID: PM6286
- Base Year: 2024
- Historical Data: 2020-2023
Overview
The global enzymatic DNA synthesis market size was valued at USD0020284.26 million in 2024, growing at a CAGR of 26.85% from 2025 to 2034. Key factors driving demand for enzymatic DNA synthesis include expanding biotechnology sector coupled with growing research funding in genomic research and drug development.
Key Insights
- The oligonucleotide synthesis materials segment dominated the market share in 2024.
- The vaccine development segment is projected to grow at a rapid pace in the coming years, supported by the increasing reliance on synthetic DNA technologies for rapid response platforms against infectious diseases and pandemics.
- The North America enzymatic DNA synthesis market dominated the global market share in 2024.
- The U.S. enzymatic DNA synthesis market is growing, driven by a well-established infrastructure of contract research organizations (CROs) and academic research institutes that support large-scale adoption of advanced DNA synthesis tools.
- The market in Asia Pacific is projected to grow at a fast pace from 2025-2034, fueled by rising government funding and national initiatives focused on synthetic biology and life sciences innovation.
- The market in China is growing, attributed to the rapid growth in genomics and biotech research alongside expanding pharmaceutical R&D capabilities.
Industry Dynamics
- Expanding biotechnology sector is driving demand for enzymatic DNA synthesis technologies, as research institutions and biopharma companies accelerate drug discovery, synthetic biology, and vaccine development.
- Growing research funding in genomics and drug development is fueling adoption, with governments and private investors supporting next-generation DNA synthesis platforms for faster and more precise results.
- Integration of AI and machine learning presents significant opportunities for market growth, enabling automated sequence design, enhanced error correction, and streamlined synthesis workflows.
- High R&D costs and limited commercial-scale production capabilities continue to restrain market expansion, restricting accessibility for smaller research organizations and slowing widespread adoption.
Market Statistics
- 2024 Market Size: USD 284.26 Million
- 2034 Projected Market Size: USD 3,063.36 Million
- CAGR (2025–2034): 26.85%
- North America: Largest Market Share
The enzymatic DNA synthesis market comprises innovative technologies and platforms designed to produce DNA sequences with high precision, speed, and scalability. Widely utilized in pharmaceuticals, biotechnology, diagnostics, synthetic biology, and academic research, enzymatic DNA synthesis enables rapid gene assembly, personalized medicine development, and advanced genomic studies. Rising advancements in enzyme engineering, automation, and error-correction methods are enhancing synthesis accuracy, efficiency, and cost-effectiveness. Offering sustainability, reduced reliance on hazardous chemicals, and compatibility with diverse research and industrial applications, enzymatic DNA synthesis solutions accelerate innovation, support next-generation therapeutics, and contribute to the growth of precision medicine and synthetic biology.
Technological progress in enzymatic DNA synthesis is transforming the ability to generate long, accurate, and complex DNA sequences for advanced research and therapeutic applications. Continuous innovation in enzyme engineering, error correction, and automation is enabling faster synthesis cycles, higher fidelity, and reduced production costs compared to traditional chemical methods. For instance, in February 2025, Scientists in Paris made progress in enzymatic DNA synthesis technology aimed at streamlining mRNA vaccine development. With USD 4.7 million in CEPI funding, DNA Script is working to automate the production of synthetic DNA templates, reducing vaccine timelines and improving accessibility, particularly across the Global South. These developments are accelerating the adoption of enzymatic methods across research institutes, biopharmaceutical companies, and diagnostic providers seeking next-generation DNA solutions.
Rising focus on personalized and precision medicine is further fueling demand of genomics and synthetic DNA for targeted therapies, diagnostics, and drug discovery services. Growing investment in genomics programs, coupled with advancements in CRISPR-based editing and gene therapies, is driving demand for custom DNA synthesis tailored to individual patient needs. The ability of enzymatic DNA synthesis to provide faster turnaround, sustainable manufacturing, and higher sequence complexity is positioning it as a critical enabler of precision healthcare. Expanding applications in oncology, rare disease treatment, and molecular diagnostics are reinforcing strong market growth, creating opportunities for providers to supply innovative, scalable, and clinically relevant synthesis solutions to meet evolving healthcare demands.
Drivers & Opportunities
Expanding Biotechnology Sector Driving Adoption of Advanced DNA Synthesis Technologies: The rapid growth of the global biotechnology sector is fueling demand for next-generation DNA synthesis platforms, as innovations in biopharma, agricultural biotechnology, and industrial biotechnology increasingly rely on precise and scalable DNA solutions. Enzymatic DNA synthesis is growing due to its ability to deliver faster, more accurate, and environmentally sustainable DNA production compared to traditional chemical methods. According to India’s Ministry of Science & Technology, the country’s bioeconomy expanded from USD 10 billion in 2014 to USD 165.7 billion in 2024, with projections to reach USD 300 billion by 2030. This exponential growth reflects rising investment in genomics, synthetic biology, and life sciences research, underscoring the growing importance of advanced DNA synthesis technologies in supporting global biotechnological innovation and commercialization.
Growing Research Funding in Genomic Research and Drug Development: Increasing funding for genomic research, drug development, and molecular diagnostics is increasing the demand for enzymatic DNA synthesis. Governments and institutions are scaling investments to accelerate genomics-driven innovation and enhance healthcare outcomes. For example, in June 2025, Genome Canada, serving as a lead delivery partner in the Government of Canada’s Canadian Genomics Strategy (CGS), announced over USD 6 million in funding for five projects, complemented by approximately USD 12 million in co-investment through regional Genome Centres. This initiative reflects a broader trend of sustained funding for genomics research, boosting demand for enzymatic DNA synthesis as a key enabling technology for advancing drug discovery, precision medicine, and agricultural innovation.
Segmental Insights
By Services
Based on services, the enzymatic DNA synthesis market is segmented into oligonucleotide synthesis and gene synthesis. Oligonucleotide synthesis accounted for the largest share in 2024, due to its extensive use in molecular diagnostics, PCR assays, next-generation sequencing, and targeted drug discovery. The increasing demand for customized oligos in therapeutic research and biomarker identification is further driving the growth of this segment.
Gene synthesis is projected to register robust growth during the forecast period, driven by rising adoption in synthetic biology, genetic engineering, and vaccine development. Its ability to enable precise, large-scale, and cost-efficient DNA assembly makes it a vital tool for developing engineered organisms, advanced therapeutics, and novel biotechnological applications.
By Technology
Based on technology, the market is categorized into SOLA, CRISPR, and PCR. PCR held the largest share in 2024, owing to its established use in research and clinical diagnostics, enabling high-throughput DNA amplification for genetic analysis, infectious disease detection, and oncology applications.
CRISPR is expected to grow significantly, fueled by its transformative role in genome editing, targeted gene modifications, and therapeutic research. The increasing number of CRISPR-based projects in drug discovery and agricultural biotechnology is strengthening the growth of this segment. For instance, in March 2025, Scientists at Yale University developed advanced CRISPR-Cas9 mouse models capable of simultaneously editing multiple genes to investigate genetic interactions across various diseases including cancer, marking a significant leap in disease modeling capabilities.
By Application
Based on application, the enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, vaccine development, and others. Synthetic biology dominated the market in 2024, driven by its widespread use in designing genetic circuits, metabolic engineering, and developing bio-based materials and fuels.
Vaccine development is expected to record substantial growth, supported by the increasing reliance on synthetic DNA technologies for rapid response platforms against infectious diseases and pandemics. Genetic engineering applications continue to expand in agricultural biotechnology and biopharmaceutical development, further contributing to market expansion.
By End Use
Based on end use, the market is divided into biopharmaceutical companies, academic & research institutes, and contract research organizations. Biopharmaceutical companies accounted for the largest share in 2024, driven by its focus on developing gene-based therapies, precision medicine, and biologics that require efficient and scalable DNA synthesis solutions.
Academic & research institutes represent a growing segment, supported by increasing investments in genomics, molecular diagnostics, and synthetic biology research. Contract research organizations are expected to witness steady growth as outsourcing of DNA synthesis services becomes a cost-effective strategy for smaller firms and startups aiming to accelerate research timelines and reduce operational costs.
Regional Analysis
The North America enzymatic DNA synthesis market accounted for the largest share in 2024, attributed to the strong presence of leading biotechnology and pharmaceutical companies that are driving early adoption of next-generation DNA synthesis technologies. Significant funding from the National Institutes of Health (NIH) and private investors for genomics, synthetic biology, and precision medicine research is strengthening market expansion across the region. Growing collaboration between biopharmaceutical firms and technology developers is further accelerating innovation and commercial adoption.
U.S. Enzymatic DNA Synthesis Market Overview
The U.S. enzymatic DNA synthesis market held a dominant position in North America, driven by a well-established infrastructure of contract research organizations (CROs) and academic research institutes that support large-scale adoption of advanced DNA synthesis tools. Public and private funding in life sciences is propelling the demand for high-throughput and efficient synthesis technologies. According to the Association of Clinical Research Organizations, the U.S. CRO market is projected to reach USD 94.61 billion by 2029, highlighting the robust environment supporting enzymatic DNA synthesis adoption in clinical and research applications.
Asia Pacific Enzymatic DNA Synthesis Market Insights
The Asia Pacific enzymatic DNA synthesis market is projected to witness the fastest growth during the forecast period, fueled by rising government funding and national initiatives focused on synthetic biology and life sciences innovation. Expanding pharmaceutical manufacturing bases across the region are creating demand for cost-effective DNA synthesis solutions to support drug discovery and large-scale production. The region’s increasing emphasis on biotechnology-driven healthcare advancements and agricultural innovation is further boosting the growth of the market.
China Enzymatic DNA Synthesis Market Analysis
China enzymatic DNA synthesis market captured the largest share in Asia Pacific, owing to the rapid growth in genomics and biotech research alongside expanding pharmaceutical R&D capabilities. Strong government support and large-scale funding initiatives are fueling the country’s position as a biotechnology hub. According to the Observer Research Foundation, in March 2025, China announced the establishment of a national venture capital guidance fund, a public-private partnership (PPP)-based vehicle designed to mobilize USD 138 billion. This fund aims to accelerate entrepreneurship in disruptive technologies, including biotechnology and artificial intelligence, thereby creating a favorable ecosystem for enzymatic DNA synthesis innovation.
Europe Enzymatic DNA Synthesis Market Assessment
The Europe enzymatic DNA synthesis market accounted for a substantial global share in 2024, attributed to the strict focus on sustainability and green chemistry that is accelerating the transition from chemical to enzymatic DNA synthesis methods. Large-scale EU-funded genomics and bioeconomy projects are driving the integration of enzymatic DNA synthesis into agricultural biotechnology, healthcare, and environmental research. For instance, EU stakeholders are prioritizing genomic and biobanking initiatives through key funding programs. Horizon Europe, with a EUR 95.5 billion budget (2021–2027), serves as the primary R&I framework, supporting genomics projects under initiatives such as “1+ Million Genomes. Countries such as Germany, France, and the UK are at the forefront of deploying enzymatic synthesis technologies to meet with sustainability goals while expanding research capacity in genetic engineering and synthetic biology.
Key Players & Competitive Analysis
The global enzymatic DNA synthesis market is highly competitive, with leading players such as DNA Script SAS, Twist Bioscience Corporation, and Molecular Assemblies, Inc. advancing the industry through breakthroughs in enzyme engineering, proprietary synthesis platforms, and scalable production technologies. DNA Script SAS strengthened its position with benchtop enzymatic DNA synthesis systems that enable on-demand oligonucleotide production, while Twist Bioscience Corporation continues to expand its portfolio of high-throughput DNA products for drug discovery, genomics, and industrial biotech applications. Molecular Assemblies, Inc. is focused on developing next-generation enzymatic synthesis methods that deliver higher accuracy, faster turnaround, and reduced reliance on chemical reagents.
The market is witnessing increasing adoption of enzymatic DNA synthesis in genomics, synthetic biology, and precision medicine, driven by demand for sustainable, error-free, and scalable DNA manufacturing processes. Companies are prioritizing the development of platform-based solutions that combine automation, AI-driven sequence design, and miniaturized synthesis systems to improve cost efficiency and speed. Strategic partnerships with pharmaceutical companies, biotech firms, and academic institutions are accelerating commercialization. Furthermore, sustainability-focused R&D initiatives aimed at reducing hazardous chemical waste are positioning enzymatic DNA synthesis as a green alternative to traditional phosphoramidite chemistry.
Prominent companies operating in the enzymatic DNA synthesis market include Aldevron LLC (Danaher Corporation), Almac Group Limited, Ansa Biotechnologies, Inc., Biotium, Inc., Camena Bioscience Ltd., DNA Script SAS, Elegen Corporation, Evonetix Ltd., GenScript Biotech Corporation, Kern Systems, Inc., Merck KGaA, Molecular Assemblies, Inc., Telesis Bio Inc., Touchlight Genetics Ltd., and Twist Bioscience Corporation.
Key Players
- Aldevron LLC (Danaher Corporation)
- Almac Group Limited
- Ansa Biotechnologies, Inc.
- Biotium, Inc.
- Camena Bioscience Ltd.
- DNA Script SAS
- Elegen Corporation
- Evonetix Ltd.
- GenScript Biotech Corporation
- Kern Systems, Inc.
- Merck KGaA
- Molecular Assemblies, Inc.
- Telesis Bio Inc.
- Touchlight Genetics Ltd.
- Twist Bioscience Corporation
Enzymatic DNA Synthesis Industry Developments
In May 2025, Ansa Biotechnologies introduced a 50 kb DNA synthesis early access program, delivering ultra-long and complex DNA sequences in less than four weeks. This achievement highlights the scalability and efficiency of enzymatic DNA synthesis for genomics, agriculture, synthetic biology, and cell and gene therapy, further highlighting its role in meeting the growing demand for high-quality synthetic DNA.
In May 2025, Telesis Bio licensed its Gibson SOLA enzymatic synthesis platform to Regeneron, enabling high-throughput, on-demand gene synthesis directly within Regeneron’s R&D facilities. This partnership is designed to accelerate biologics discovery by cutting DNA and mRNA production timelines from weeks to just hours, reflecting the rising adoption of enzymatic DNA synthesis for flexible, in-house applications.
Enzymatic DNA Synthesis Market Segmentation
By Services Outlook (Revenue, USD Million, 2020–2034)
- Oligonucleotide Synthesis
- Gene Synthesis
By Technology Outlook (Revenue, USD Million, 2020–2034)
- SOLA
- CRISPR
- PCR
By Application Outlook (Revenue, USD Million, 2020–2034)
- Synthetic Biology
- Genetic Engineering
- Vaccine Development
- Others
By End Use Outlook (Revenue, USD Million, 2020–2034)
- Biopharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations
By Regional Outlook (Revenue, USD Million, 2020–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Enzymatic DNA Synthesis Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 284.26 Million |
|
Market Size in 2025 |
USD 360.17 Million |
|
Revenue Forecast by 2034 |
USD 3,063.36 Million |
|
CAGR |
26.85% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
© 2025 Polaris Market Research and Consulting. All rights reserved
